MichaelEHurwitzMD

Oncology • New Haven, CT

Assistant Professor of Medicine, Division of Oncology, Yale University School of Medicine

Join to view full profile

Dr. Hurwitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hurwitz's full profile

Already have an account?

Office
333 Cedar St
Yale University School Of Medicine
New Haven, CT 06510
Phone+1 203-200-4822

Fax+1 203-200-2099

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2004
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1998 - 2000
Weill Cornell MedicineClass of 1998

Certifications & Licensure

CT State Medical License 2010 - 2025
MA State Medical License 2000 - 2010

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Start of enrollment: 2018 Feb 06
Terminated
Early Phase 1
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer Start of enrollment: 2019 Dec 23
Completed
Phase 2
Roles: Contact, Principal Investigator
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Start of enrollment: 2018 Jun 19
Recruiting
Phase 3
Roles: Contact
A Study to Investigate LYL845 in Adults With Solid Tumors Start of enrollment: 2022 Dec 19
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy.
Rebecca Forman, Jessica B Long, Sarah J Westvold, Khushi Agnish, Hannah D Mcmanus
JNCI Cancer Spectrum. 2024-09-02
1 citations
TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3.
Oscar Perales, Lucia Jilaveanu, Adebowale Adeniran, David G Su, Michael Hurwitz
Cancer Immunology, Immunotherapy. 2024-08-06
11 citations
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Sumanta K Pal, Ben Tran, John B A G Haanen, Michael E Hurwitz, Adrian Sacher
Cancer Discovery. 2024-07-01

Lectures

Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

CAR T Cell Therapy May Eliminate Tumor Cells Missed by SurgeryFebruary 9th, 2023
Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers SymposiumFebruary 19th, 2017
'We're Not There yet': CAR T-cell Therapy for Renal Cell CarcinomaNovember 17th, 2023

Grant Support

Screening Of Synthetic Lethality With C. Elegans RBNational Cancer Institute2004–2008